Publications

  1. Saiki H, Moulay G, Guenzel AJ, Liu W, Decklever TD, Classic KL, Pham L, Chen HH, Burnett JC, Russell SJ, Redfield MM. Experimental cardiac radiation exposure induces ventricular diastolic dysfunction with preserved ejection fraction. Am J Physiol Heart Circ Physiol. 2017 Aug 01; 313 (2):H392-H407 Epub 2017 May 26
    View PubMed
  2. Jain A, Scott C, Chen HH. The renal-cardiac connection in subjects with preserved ejection fraction: a population based study. ESC Heart Fail. 2017 Aug; 4 (3):266-273 Epub 2017 May 16
    View PubMed
  3. Grodin JL, Gallup D, Anstrom KJ, Felker GM, Chen HH, Tang WHW. Implications of Alternative Hepatorenal Prognostic Scoring Systems in Acute Heart Failure (from DOSE-AHF and ROSE-AHF). Am J Cardiol. 2017 Jun 15; 119 (12):2003-2009 Epub 2017 Mar 29
    View PubMed
  4. AbouEzzeddine OF, McKie PM, Dunlay SM, Stevens SR, Felker GM, Borlaug BA, Chen HH, Tracy RP, Braunwald E, Redfield MM. Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc. 2017 Feb 18; 6 (2)
    View PubMed
  5. Grodin JL, Sun JL, Anstrom KJ, Chen HH, Starling RC, Testani JM, Tang WH. Implications of Serum Chloride Homeostasis in Acute Heart Failure (from ROSE-AHF). Am J Cardiol. 2017 Jan 01; 119 (1):78-83 Epub 2016 Sept 30
    View PubMed
  6. Gandhi PU, Gaggin HK, Redfield MM, Chen HH, Stevens SR, Anstrom KJ, Semigran MJ, Liu P, Januzzi JL Jr. Insulin-Like Growth Factor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction: Results From the RELAX Trial. JACC Heart Fail. 2016 Nov; 4 (11):860-869 Epub 2016 Oct 12
    View PubMed
  7. AbouEzzeddine OF, McKie PM, Scott CG, Rodeheffer RJ, Chen HH, Michael Felker G, Jaffe AS, Burnett JC, Redfield MM. Biomarker-based risk prediction in the community. Eur J Heart Fail. 2016 Nov; 18 (11):1342-1350
    View PubMed
  8. Torres-Courchoud I, Chen HH. B-type natriuretic peptide and acute heart failure: Fluid homeostasis, biomarker and therapeutics. Rev Clin Esp. 2016 Oct; 216: (7)393-398.
    View PubMed
  9. Wan SH, Stevens SR, Borlaug BA, Anstrom KJ, Deswal A, Felker GM, Givertz MM, Bart BA, Tang WH, Redfield MM, Chen HH. Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure). Circ Heart Fail. 2016 Aug; 9: (8).
    View PubMed
  10. Kelly JP, Cooper LB, Gallup D, Anstrom KJ, Chen HH, Redfield MM, O'Connor CM, Mentz RJ, Hernanadez AF, Felker GM. Implications of Using Different Definitions on Outcomes in Worsening Heart Failure. Circ Heart Fail. 2016 Aug; 9: (8).
    View PubMed
  11. Wan SH, Stevens SR, Borlaug BA, Anstrom KJ, Deswal A, Felker GM, Givertz MM, Bart BA, Tang WHW, Redfield MM, Chen HH. Differential response to low-dose dopamine or low-dose nesiritide in acute heart failure with reduced or preserved ejection fraction results from the rose ahf trial (renal optimization strategies evaluation in acute heart failure) Circulation-Heart Failure. 2016 Aug; 9: (8)e002593.
  12. Wan SH, McKie PM, Schirger JA, Slusser JP, Hodge DO, Redfield MM, Burnett JC Jr, Chen HH. Chronic Peptide Therapy With B-Type Natriuretic Peptide in Patients With Pre-Clinical Diastolic Dysfunction (Stage B Heart Failure). JACC Heart Fail. 2016 Jul; 4 (7):539-547 Epub 2016 Feb 10
    View PubMed
  13. Patel PA, Scott CG, Rodeheffer RJ, Chen HH. The Natural History of Patients With Isolated Metabolic Syndrome. Mayo Clin Proc. 2016 May; 91: (5)623-33.
    View PubMed
  14. McKie PM, Schirger JA, Benike SL, Harstad LK, Slusser JP, Hodge DO, Redfield MM, Burnett JC Jr, Chen HH. Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure. Eur J Heart Fail. 2016 Apr; 18 (4):433-41 Epub 2016 Jan 24
    View PubMed
  15. AbouEzzeddine OF, Lala A, Khazanie PP, Shah R, Ho JE, Chen HH, Pang PS, McNulty SE, Anstrom KJ, Hernandez AF, Redfield MM, NHLBI Heart Failure Clinical Research Network. Evaluation of a provocative dyspnea severity score in acute heart failure. Am Heart J. 2016 Feb; 172:34-41.
    View PubMed
  16. Huang Y, Ng XW, Lim SG, Chen HH, Burnett JC Jr, Boey YC, Venkatraman SS. In vivo Evaluation of Cenderitide-Eluting Stent (CES) II. Ann Biomed Eng. 2016 Feb; 44: (2)432-41.
    View PubMed
  17. Grodin JL, Stevens SR, de Las Fuentes L, Kiernan M, Birati EY, Gupta D, Bart BA, Felker GM, Chen HH, Butler J, Davila-Roman VG, Margulies KB, Hernandez AF, Anstrom KJ, Tang WH. Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure. J Card Fail. 2016 Jan; 22: (1)26-32.
    View PubMed
  18. Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, LeWinter MM, Joseph SM, Shah SJ, Semigran MJ, Felker GM, Cole RT, Reeves GR, Tedford RJ, Tang WH, McNulty SE, Velazquez EJ, Shah MR, Braunwald E, NHLBI Heart Failure Clinical Research Network. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2015 Dec 10; 373: (24)2314-24.
    View PubMed
  19. Sangaralingham SJ, McKie PM, Ichiki T, Scott CG, Heublein DM, Chen HH, Bailey KR, Redfield MM, Rodeheffer RJ, Burnett JC Jr. Circulating C-type natriuretic peptide and its relationship to cardiovascular disease in the general population. Hypertension. 2015 Jun; 65: (6)1187-94.
    View PubMed
  20. Borlaug BA, Lewis GD, McNulty SE, Semigran MJ, LeWinter M, Chen H, Lin G, Deswal A, Margulies KB, Redfield MM. Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction. Circ Heart Fail. 2015 May; 8: (3)533-41.
    View PubMed
  21. AbouEzzeddine OF, Haines P, Stevens S, Nativi-Nicolau J, Felker GM, Borlaug BA, Chen HH, Tracy RP, Braunwald E, Redfield MM. Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure). JACC Heart Fail. 2015 Mar; 3: (3)245-52.
    View PubMed
  22. Patel P, Chen HH. Natriuretic Peptides as a Novel Target in Resistant Hypertension. Curr Hypertens Rep. 2015 Mar; 17 (3):18
    View PubMed
  23. Wan SH, Chen HH. Targeting preclinical diastolic dysfunction to prevent heart failure: contemporary insights. Current Cardiovascular Risk Reports. 2015; 9(8):40.
  24. Ng XW, Huang Y, Liu KL, Lim SG, Chen HH, Burnett JC Jr, Freddy Boey YC, Venkatraman SS. In vitro evaluation of cenderitide-eluting stent I -an antirestenosis and proendothelization approach. J Pharm Sci. 2014 Nov; 103 (11):3631-3640 Epub 2014 Sept 15
    View PubMed
  25. Torres-Courchoud I, Chen HH. Is there still a role for low-dose dopamine use in acute heart failure? Curr Opin Crit Care. 2014 Oct; 20(5):467-71.
    View PubMed
  26. Jain AK, Chen HH. ROSE-AHF and lessons learned. Curr Heart Fail Rep. 2014 Sep; 11: (3)260-5.
    View PubMed
  27. Grodin JL, Stevens SR, Fuentes Lde L, Kiernan M, Birati EY, Gupta D, Bart BA, Felker M, Chen HH, Butler J, Davila-Roman VG, Margulies KB, Hernandez A, Anstrom K, Tang WH. A Stepwise Pharmacological Care Algorithm for Cardiorenal Syndrome for Acute Heart Failure: Insights from DOSE-AHF, CARRESS-HF, and ROSE-AHF. J Card Fail. 2014 Aug; 20(8 Suppl):S13.
    View PubMed
  28. Patel PA, Scott C, Rodeheffer R, Chen H. The natural history of subjects with isolated metabolic syndrome- a population based study. J Card Fail. 2014 Aug; 20(8 Suppl):S110.
    View PubMed
  29. Dandamudi S, Slusser J, Mahoney DW, Redfield MM, Rodeheffer RJ, Chen HH. The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota. J Card Fail. 2014 May; 20: (5)304-9.
    View PubMed
  30. Wan SH, Vogel MW, Chen HH. Pre-clinical diastolic dysfunction. J Am Coll Cardiol. 2014 Feb 11; 63: (5)407-16.
    View PubMed
  31. McKie PM, Cataliotti A, Ichiki T, Sangaralingham SJ, Chen HH, Burnett JC Jr. M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics. J Am Heart Assoc. 2014 Jan 02; 3: (1)e000206.
    View PubMed
  32. Hoffmann LS, Chen HH. cGMP: Transition from bench to bedside: A report of the 6th International Conference on cGMP Generators, Effectors and Therapeutic Implications. Naunyn-Schmiedeberg's Archives of Pharmacology. 2014; 387:707-18.
    View PubMed
  33. Pan S, Chen HH, Correia C, Dai H, Witt TA, Kleppe LS, Burnett JC Jr, Simari RD. Cell surface protein disulfide isomerase regulates natriuretic peptide generation of cyclic guanosine monophosphate. PLoS One. 2014; 9: (11)e112986.
    View PubMed
  34. Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, Bart BA, Bull DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL, O'Meara E, Tang WH, Starling RC, Butler J, Deswal A, Felker GM, O'Connor CM, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, Davila-Roman VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM, NHLBI Heart Failure Clinical Research Network. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA. 2013 Dec 18; 310: (23)2533-43.
    View PubMed
  35. Chen HH, AbouEzzeddine OF, Anstrom KJ, Givertz MM, Bart BA, Felker GM, Hernandez AF, Lee KL, Braunwald E, Redfield MM, Heart Failure Clinical Research Network. Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial. Circ Heart Fail. 2013 Sep 01; 6: (5)1087-94.
    View PubMed
  36. Sangaralingham SJ, Burnett JC Jr, McKie PM, Schirger JA, Chen HH. Rationale and design of a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of B-type natriuretic peptide for the preservation of left ventricular function after anterior myocardial infarction. J Card Fail. 2013 Aug; 19: (8)533-9.
    View PubMed
  37. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E, RELAX Trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013 Mar 27; 309: (12)1268-77.
    View PubMed
  38. Lim SG, Venkatraman SS, Burnett JC Jr, Chen HH. In-vivo evaluation of an in situ polymer precipitation delivery system for a novel natriuretic peptide. PLoS One. 2013; 8(2):e52484. Epub 2013 Feb 18.
    View PubMed
  39. Ng XW, Huang Y, Chen HH, Burnett JC Jr, Boey FY, Venkatraman SS. Cenderitide-eluting film for potential cardiac patch applications. PLoS One. 2013; 8(7):e68346. Epub 2013 Jul 04.
    View PubMed
  40. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O'Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E, Heart Failure Clinical Research Network. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012 Dec 13; 367(24):2296-304. Epub 2012 Nov 06.
    View PubMed
  41. Chen HH, Glockner JF, Schirger JA, Cataliotti A, Redfield MM, Burnett JC Jr. Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. J Am Coll Cardiol. 2012 Dec 04; 60: (22)2305-12.
    View PubMed
  42. Bishu K, Deswal A, Chen HH, LeWinter MM, Lewis GD, Semigran MJ, Borlaug BA, McNulty S, Hernandez AF, Braunwald E, Redfield MM. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. Am Heart J. 2012 Nov; 164: (5)763-770.e3.
    View PubMed
  43. Macheret F, Heublein D, Costello-Boerrigter LC, Boerrigter G, McKie P, Bellavia D, Mangiafico S, Ikeda Y, Bailey K, Scott CG, Sandberg S, Chen HH, Malatino L, Redfield MM, Rodeheffer R, Burnett J Jr, Cataliotti A. Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP. J Am Coll Cardiol. 2012 Oct 16; 60(16):1558-65.
    View PubMed
  44. Clements IP, Akerem Khan SK, Chen HH, Mullan BP. Measurement of left and right ventricular volumes with tomographic equilibrium radionuclide angiocardiography and cardiac MRI. Nucl Med Commun. 2012 May; 33: (5)481-5.
    View PubMed
  45. Dandamudi S, Chen HH. The ASCEND-HF trial: an acute study of clinical effectiveness of nesiritide and decompensated heart failure. Expert Rev Cardiovasc Ther. 2012 May; 10(5):557-63.
    View PubMed
  46. Vogel MW, Slusser JP, Hodge DO, Chen HH. The natural history of preclinical diastolic dysfunction: a population-based study. Circ Heart Fail. 2012 Mar 1; 5: (2)144-51.
    View PubMed
  47. Bart BA, Goldsmith SR, Lee KL, Redfield MM, Felker GM, O'Connor CM, Chen HH, Rouleau JL, Givertz MM, Semigran MJ, Mann D, Deswal A, Bull DA, Lewinter MM, Braunwald E. Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network. J Card Fail. 2012 Mar; 18(3):176-82. Epub 2012 Feb 02.
    View PubMed
  48. Martin FL, McKie PM, Cataliotti A, Sangaralingham SJ, Korinek J, Huntley BK, Oehler EA, Harders GE, Ichiki T, Mangiafico S, Nath KA, Redfield MM, Chen HH, Burnett JC Jr. Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection. Am J Physiol Regul Integr Comp Physiol. 2012 Jan 15; 302: (2)R292-9.
    View PubMed
  49. Martin FL, Sangaralingham SJ, Huntley BK, McKie PM, Ichiki T, Chen HH, Korinek J, Harders GE, Burnett JC Jr. CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart. PLoS One. 2012; 7: (12)e52422.
    View PubMed
  50. Dandamudi S, Chen HH. Evolving treatment strategies for management of cardiorenal syndrome. Curr Treat Options Cardiovasc Med. 2011 Dec; 13 (6):556-69
    View PubMed
  51. McKie PM, Schirger JA, Costello-Boerrigter LC, Benike SL, Harstad LK, Bailey KR, Hodge DO, Redfield MM, Simari RD, Burnett JC Jr, Chen HH. Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction. J Am Coll Cardiol. 2011 Nov 8; 58: (20)2095-103.
    View PubMed
  52. Dong YX, Burnett JC Jr, Chen HH, Sandberg S, Yang YZ, Zhang Y, Chen PS, Cha YM. Effect of cardiac resynchronization therapy on broad neurohormone biomarkers in heart failure. J Interv Card Electrophysiol. 2011 Apr; 30 (3):241-9 Epub 2011 Feb 19
    View PubMed
  53. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O'Connor CM, NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011 Mar 3; 364(9):797-805.
    View PubMed
  54. Vogel MW, Chen HH. Novel natriuretic peptides: new compounds and new approaches. Curr Heart Fail Rep. 2011 Mar; 8 (1):22-7
    View PubMed
  55. Sangaralingham SJ, Huntley BK, Martin FL, McKie PM, Bellavia D, Ichiki T, Harders GE, Chen HH, Burnett JC Jr. The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic Peptide. Hypertension. 2011 Feb; 57: (2)201-7.
    View PubMed
  56. McKie PM, Cataliotti A, Boerrigter G, Chen HH, Sangaralingham SJ, Martin FL, Ichiki T, Burnett JC Jr. A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension. Hypertension. 2010 Dec; 56: (6)1152-9.
    View PubMed
  57. Huntley BK, Ichiki T, Sangaralingham SJ, Chen HH, Burnett JC Jr. B-type natriuretic peptide and extracellular matrix protein interactions in human cardiac fibroblasts. J Cell Physiol. 2010 Oct; 225: (1)251-5.
    View PubMed
  58. Boilson BA, Larsen K, Harbuzariu A, Delacroix S, Korinek J, Froehlich H, Bailey KR, Scott CG, Shapiro BP, Boerrigter G, Chen HH, Redfield MM, Burnett JC Jr, Simari RD. Regulation of circulating progenitor cells in left ventricular dysfunction. Circ Heart Fail. 2010 Sep; 3: (5)635-42.
    View PubMed
  59. Correa de Sa DD, Hodge DO, Slusser JP, Redfield MM, Simari RD, Burnett JC, Chen HH. Progression of preclinical diastolic dysfunction to the development of symptoms. Heart. 2010 Apr; 96: (7)528-32.
    View PubMed
  60. From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol. 2010 Jan 26; 55: (4)300-5.
    View PubMed
  61. Chen HH, Martin FL, Gibbons RJ, Schirger JA, Wright RS, Schears RM, Redfield MM, Simari RD, Lerman A, Cataliotti A, Burnett JC Jr. Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study. Heart. 2009 Aug; 95: (16)1315-9.
    View PubMed
  62. Pan S, Chen HH, Dickey DM, Boerrigter G, Lee C, Kleppe LS, Hall JL, Lerman A, Redfield MM, Potter LR, Burnett JC Jr, Simari RD. Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide. Proc Natl Acad Sci U S A. 2009 Jul 07; 106: (27)11282-7.
    View PubMed
  63. Lee CY, Chen HH, Lisy O, Swan S, Cannon C, Lieu HD, Burnett JC Jr. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol. 2009 Jun; 49: (6)668-73.
    View PubMed
  64. From AM, Scott CG, Chen HH. Changes in diastolic dysfunction in diabetes mellitus over time. Am J Cardiol. 2009 May 15; 103: (10)1463-6.
    View PubMed
  65. Chen HH, Cataliotti A, Schirger JA, Martin FL, Harstad LK, Burnett JC Jr. Local renal delivery of a natriuretic peptide a renal-enhancing strategy for B-type natriuretic peptide in overt experimental heart failure. J Am Coll Cardiol. 2009 Apr 14; 53: (15)1302-8.
    View PubMed
  66. Martin FL, Chen HH, Cataliotti A, Burnett JC Jr. Targeting the kidney in acute decompensated heart failure: conventional diuretics and renal-acting vasodilators. Rev Cardiovasc Med. 2008 Winter; 9(1):39-45.
    View PubMed
  67. Cataliotti A, Chen HH, Schirger JA, Martin FL, Boerrigter G, Costello-Boerrigter LC, James KD, Polowy K, Miller MA, Malkar NB, Bailey KR, Burnett JC Jr. Chronic actions of a novel oral B-type natriuretic peptide conjugate in normal dogs and acute actions in angiotensin II-mediated hypertension. Circulation. 2008 Oct 21; 118: (17)1729-36.
    View PubMed
  68. Martin FL, Chen HH, Cataliotti A, Burnett JC Jr. B-type natriuretic peptide: beyond a diagnostic. Heart Fail Clin. 2008 Oct; 4: (4)449-54.
    View PubMed
  69. Mohammed SF, Korinek J, Chen HH, Burnett JC, Redfield MM. Nesiritide in acute decompensated heart failure: current status and future perspectives. Rev Cardiovasc Med. 2008 Summer; 9: (3)151-8.
    View PubMed
  70. de Sa DD, Chen HH. The role of natriuretic peptides in heart failure. Curr Cardiol Rep. 2008 May; 10 (3):182-9
    View PubMed
  71. Owan TE, Chen HH, Frantz RP, Karon BL, Miller WL, Rodeheffer RJ, Hodge DO, Burnett JC Jr, Redfield MM. The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction. J Card Fail. 2008 May; 14: (4)267-75.
    View PubMed
  72. Martin FL, Supaporn T, Chen HH, Sandberg SM, Matsuda Y, Jougasaki M, Burnett JC Jr. Distinct roles for renal particulate and soluble guanylyl cyclases in preserving renal function in experimental acute heart failure. Am J Physiol Regul Integr Comp Physiol. 2007 Oct; 293(4):R1580-5. Epub 2007 Aug 01.
    View PubMed
  73. Chen HH, Sundt TM, Cook DJ, Heublein DM, Burnett JC Jr. Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study. Circulation. 2007 Sep 11; 116(11 Suppl):I134-8.
    View PubMed
  74. Binder J, Ommen SR, Chen HH, Ackerman MJ, Tajik AJ, Jaffe AS. Usefulness of brain natriuretic peptide levels in the clinical evaluation of patients with hypertrophic cardiomyopathy. Am J Cardiol. 2007 Aug 15; 100: (4)712-4.
    View PubMed
  75. Cataliotti A, Chen HH, James KD, Burnett JC Jr. Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular disease. Trends Cardiovasc Med. 2007 Jan; 17(1):10-4.
    View PubMed
  76. Chen HH, Schrier RW. Pathophysiology of volume overload in acute heart failure syndromes. Am J Med. 2006 Dec; 119(12 Suppl 1):S11-6.
    View PubMed
  77. Chen HH, Schirger JA, Cataliotti A, Burnett JC Jr. Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure. Eur J Heart Fail. 2006 Nov; 8(7):681-6. Epub 2006 Feb 03.
    View PubMed
  78. Belluardo P, Cataliotti A, Bonaiuto L, Giuffre E, Maugeri E, Noto P, Orlando G, Raspa G, Piazza B, Babuin L, Chen HH, Martin FL, McKie PM, Heublein DM, Burnett JC, Malatino LS. Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2006 Oct; 291(4):H1529-35. Epub 2006 Apr 28.
    View PubMed
  79. Chen HH, Huntley BK, Schirger JA, Cataliotti A, Burnett JC Jr. Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure. J Am Soc Nephrol. 2006 Oct; 17: (10)2742-7.
    View PubMed
  80. Chen HH, Burnett JC. Clinical application of the natriuretic peptides in heart failure. Eur Heart J Suppl. 2006 Sep; 8(E):E18-E25.
    View PubMed
  81. Chen HH, Burnett JC Jr. Therapeutic potential for existing and novel forms of natriuretic peptides. Heart Fail Clin. 2006 Jul; 2(3):365-73.
    View PubMed
  82. Cataliotti A, Chen HH, Redfield MM, Burnett JC Jr. Natriuretic peptides as regulators of myocardial structure and function: pathophysiologic and therapeutic implications. Heart Fail Clin. 2006 Jul; 2(3):269-76.
    View PubMed
  83. Riter H, Redfield M, Burnett JC, Chen HH. Non-hypotensive low dose nesiritide has differential renal effects compared to standard dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J Am Coll Cardiol. 2006 Jun 6; 47(11):2334-5.
  84. Bergeron S, Moller JE, Bailey KR, Chen HH, Burnett JC, Pellikka PA. Exertional changes in circulating cardiac natriuretic peptides in patients with suggested coronary artery disease. J Am Soc Echocardiogr. 2006 Jun; 19: (6)772-6.
    View PubMed
  85. Detaint D, Messika-Zeitoun D, Chen HH, Rossi A, Avierinos JF, Scott C, Burnett JC, Enriquez-Sarano M. Association of B-type natriuretic peptide activation to left ventricular end-systolic remodeling in organic and functional mitral regurgitation. Am J Cardiol. 2006 Apr 1; 97(7):1029-34. Epub 2006 Feb 28.
    View PubMed
  86. Cataliotti A, Schirger JA, Martin FL, Chen HH, McKie PM, Boerrigter G, Costello-Boerrigter LC, Harty G, Heublein DM, Sandberg SM, James KD, Miller MA, Malkar NB, Polowy K, Burnett JC Jr. Oral human brain natriuretic peptide activates cyclic guanosine 3',5'-monophosphate and decreases mean arterial pressure. Circulation. 2005 Aug 9; 112(6):836-40. Epub 2005 Aug 01.
    View PubMed
  87. Detaint D, Messika-Zeitoun D, Avierinos JF, Scott C, Chen H, Burnett JC, Enriquez-Sarano M. B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome. Circulation. 2005 May 10; 111(18):2391-7.
    View PubMed
  88. Chen HH, Cataliotti A, Schirger JA, Martin FL, Burnett JC Jr. Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure. Am J Physiol Regul Integr Comp Physiol. 2005 May; 288(5):R1093-7. Epub 2004 Dec 30.
    View PubMed
  89. Mirzoyev A, Anavekar NS, Chen HH. Renal and humoral patho physiological actions of angiotensin II in congestive heart failure. Drugs Today (Barc). 2005 Feb; 41(2):129-39.
    View PubMed
  90. Mirzoyev Z, Anavekar NS, Chen HH. Renal and humoral pathophysiological actions of angiotensin II in congestive heart failure. Timely Top Med Cardiovasc Dis. 2005; 9:E9.
    View PubMed
  91. Krajicek BJ, Chen HH. 76-year-old woman with chest pain. Mayo Clin Proc. 2004 Nov; 79(11):1435-8.
    View PubMed
  92. Cataliotti A, Boerrigter G, Costello-Boerrigter LC, Schirger JA, Tsuruda T, Heublein DM, Chen HH, Malatino LS, Burnett JC Jr. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation. 2004 Apr 6; 109(13):1680-5. Epub 2004 Mar 15.
    View PubMed
  93. Chen HH, Redfield MM, Nordstrom LJ, Horton DP, Burnett JC. Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J Card Fail. 2004 Apr; 10(2):115-9.
    View PubMed
  94. Schirger JA, Chen HH, Jougasaki M, Lisy O, Boerrigter G, Cataliotti A, Burnett JC Jr. Endothelin A receptor antagonism in experimental congestive heart failure results in augmentation of the renin-angiotensin system and sustained sodium retention. Circulation. 2004 Jan 20; 109: (2)249-54.
    View PubMed
  95. Chen HH, Redfield MM, Nordstrom LJ, Cataliotti A, Burnett JC Jr. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure. Am J Physiol Renal Physiol. 2003 May; 284(5):F1115-9.
    View PubMed
  96. Shapiro BP, Chen HH, Burnett JC Jr, Redfield MM. Use of plasma brain natriuretic peptide concentration to aid in the diagnosis of heart failure. Mayo Clin Proc. 2003 Apr; 78(4):481-6.
    View PubMed
  97. Jougasaki M, Leskinen H, Larsen AM, Cataliotti A, Chen HH, Burnett JC Jr. Leukemia inhibitory factor is augmented in the heart in experimental heart failure. Eur J Heart Fail. 2003 Mar; 5(2):137-45.
    View PubMed
  98. Tsuruda T, Boerrigter G, Huntley BK, Noser JA, Cataliotti A, Costello-Boerrigter LC, Chen HH, Burnett JC Jr. Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res. 2002 Dec 13; 91(12):1127-34.
    View PubMed
  99. Chen HH, Lainchbury JG, Senni M, Bailey KR, Redfield MM. Diastolic heart failure in the community: Clinical profile, natural history, therapy, and impact of proposed diagnostic criteria. J Card Fail. 2002 Oct; 8(5):279-87.
    View PubMed
  100. Chen HH, Lainchbury JG, Burnett JC. Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide Dendroaspis natriuretic peptide. J Am Coll Cardiol. 2002 Sep 18; 40(6):1186-91.
    View PubMed
  101. Chen HH, Lainchbury JG, Harty GJ, Burnett JC Jr. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition. Circulation. 2002 Feb 26; 105(8):999-1003.
    View PubMed
  102. Tsuruda T, Jougasaki M, Boerrigter G, Huntley BK, Chen HH, D'Assoro AB, Lee SC, Larsen AM, Cataliotti A, Burnett JC Jr. Cardiotrophin-1 stimulation of cardiac fibroblast growth: roles for glycoprotein 130/leukemia inhibitory factor receptor and the endothelin type A receptor. Circ Res. 2002 Feb 08; 90: (2)128-34.
    View PubMed
  103. Cataliotti A, Boerrigter G, Chen HH, Jougasaki M, Costello LC, Tsuruda T, Lee SC, Malatino LS, Burnett JC Jr. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure. Circulation. 2002 Feb 5; 105(5):639-44.
    View PubMed
  104. Chen HH, Cataliotti A, Burnett JC Jr. Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: insights from experimental heart failure. Curr Hypertens Rep. 2001 Dec; 3 Suppl 2:S15-21
    View PubMed
  105. Chen HH, Lainchbury JG, Matsuda Y, Harty GJ, Burnett JC Jr. Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure. Hypertension. 2001 Aug; 38: (2)187-91.
    View PubMed
  106. Chen HH, Grantham JA, Schirger JA, Jougasaki M, Redfield MM, Burnett JC Jr. Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J Am Coll Cardiol. 2000 Nov 1; 36(5):1706-12.
    View PubMed
  107. Chen HH, Burnett JC. Natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep. 2000 May; 2 (3):198-205
    View PubMed
  108. Chen HH, Oh KY, Terzic A, Burnett JC Jr. The modulating actions of sulfonylurea on atrial natriuretic peptide release in experimental acute heart failure. Eur J Heart Fail. 2000 Mar; 2(1):33-40.
    View PubMed
  109. Schirger JA, Grantham JA, Kullo IJ, Jougasaki M, Wennberg PW, Chen HH, Lisy O, Miller V, Simari RD, Burnett JC Jr. Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibition. J Am Coll Cardiol. 2000 Mar 1; 35(3):796-801.
    View PubMed
  110. Chen HH, Schirger JA, Chau WL, Jougasaki M, Lisy O, Redfield MM, Barclay PT, Burnett JC Jr. Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure. Circulation. 1999 Dec 14; 100(24):2443-8.
    View PubMed
  111. Chen HH, Burnett JC Jr. The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc Assoc Am Physicians. 1999 Sep-Oct; 111(5):406-16.
    View PubMed
  112. Lisy O, Jougasaki M, Heublein DM, Schirger JA, Chen HH, Wennberg PW, Burnett JC. Renal actions of synthetic dendroaspis natriuretic peptide. Kidney Int. 1999 Aug; 56(2):502-8.
    View PubMed
  113. Schirger JA, Heublein DM, Chen HH, Lisy O, Jougasaki M, Wennberg PW, Burnett JC Jr. Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Mayo Clin Proc. 1999 Feb; 74(2):126-30.
    View PubMed
  114. Lisy O, Jougasaki M, Schirger JA, Chen HH, Barclay PT, Burnett JC. Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin. Am J Physiol. 1998 Sep; 275(3 Pt 2):F410-4.
    View PubMed
  115. Chen HH, Burnett JC Jr. C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol. 1998; 32(Suppl 3):S22-8.
    View PubMed
  116. Chen HH, Shields RC, Bardsley WT. 68-year-old man with anemia and renal failure. Mayo Clin Proc. 1996 Feb; 71(2):197-200.
    View PubMed